View Older Stories View More Recent Stories

Nov 18, 2020 07:00AM BioLineRx Announces Initiation of Phase 1b Clinical Trial in Patients with Acute Respiratory Distress Syndrome (ARDS) Secondary to COVID-19 and Other Respiratory Viral Infections
Oct 30, 2020 07:09AM BioLineRx (BLRX) Announces Positive Results from Interim Analysis of GENESIS Phase 3 Trial of Motixafortide in Stem Cell Mobilization
Oct 30, 2020 07:00AM BioLineRx Announces Positive Results from Interim Analysis of GENESIS Phase 3 Trial of Motixafortide (BL-8040) in Stem Cell Mobilization
Oct 29, 2020 08:59AM BioLineRx (BLRX) Begins Phase 2 Clinical Trial in First-Line Metastatic Pancreatic Cancer
Oct 29, 2020 08:48AM BioLineRx Announces Initiation of Phase 2 Clinical Trial in First-Line Metastatic Pancreatic Cancer
Aug 19, 2020 07:03AM BioLineRx (BLRX) Reports Target Patient Enrollment in Phase 3 GENESIS Trial for Planned Interim Analysis
Aug 19, 2020 07:00AM BioLineRx Achieves Enrollment Target in Phase 3 GENESIS Trial for Planned Interim Analysis
Aug 6, 2020 07:00AM BioLineRx Reports Second Quarter 2020 Financial Results and Provides Corporate Update
Jul 31, 2020 07:00AM BioLineRx to Report Second Quarter 2020 Results on August 6, 2020
Jun 1, 2020 08:04AM BioLineRx (BLRX) Reports 2.51M ADS Registered Direct Offering at $1.75/ADS
Jun 1, 2020 08:00AM BioLineRx Announces $4.39 Million Registered Direct Offering
May 27, 2020 07:03AM BioLineRx (BLRX) Announces Publication of Data from Ongoing COMBAT/KEYNOTE-202 Clinical Trial in Nature Medicine
May 27, 2020 07:00AM BioLineRx Announces Publication of Data from Ongoing COMBAT/KEYNOTE-202 Clinical Trial in Nature Medicine
May 26, 2020 08:42AM BioLineRx (BLRX) Announces $9 Million Registered Direct Offering of ADSs, Warrants
May 26, 2020 08:40AM BioLineRx Announces $9.0 Million Registered Direct Offering
May 20, 2020 07:00AM BioLineRx Reports First Quarter 2020 Financial Results and Provides Corporate Update
May 15, 2020 07:00AM BioLineRx to Report First Quarter 2020 Results on May 20, 2020
Mar 12, 2020 07:00AM BioLineRx Reports Year-End 2019 Financial Results and Provides Corporate Update
Mar 6, 2020 08:00AM BioLineRx to Report Annual 2019 Results on March 12, 2020
Feb 27, 2020 08:15AM BioLineRx (BLRX) Announces Notice of Allowance from USPTO Covering Motixafortide in Combination With Anti-PD-1 for Treatment of Any Type of Cancer
Feb 27, 2020 07:43AM BioLineRx Announces Notice of Allowance from USPTO for Patent Covering Motixafortide (BL-8040) in Combination With Anti-PD-1 for the Treatment of Any Type of Cancer
Jan 22, 2020 07:00AM BioLineRx Completes Recruitment in Triple Combination Arm of COMBAT/KEYNOTE-202 Study in Patients With Second-line Metastatic Pancreatic Cancer
Jan 14, 2020 07:09AM BioLineRx (BLRX) Receives Orphan Drug Designation for Motixafortide for Treatment of Pancreatic Cancer in Europe
Jan 14, 2020 07:00AM BioLineRx Receives Orphan Drug Designation for Motixafortide (BL-8040) for the Treatment of Pancreatic Cancer in Europe
Jan 8, 2020 07:00AM BioLineRx to Present at the 2020 Biotech Showcase
Dec 13, 2019 07:04AM BioLineRx (BLRX) Reports Updated Phase 2a Data From Triple Combination Arm of COMBAT/KEYNOTE-202 Study
Dec 13, 2019 07:02AM BioLineRx Announces Updated Phase 2a Data From Triple Combination Arm of COMBAT/KEYNOTE-202 Study in Patients With Second-line Metastatic Pancreatic Cancer
Dec 5, 2019 07:14AM BioLineRx (BLRX) Reports Prelim. Ph. 2a Data from Triple Combination Arm of COMBAT/KEYNOTE-202 Study in Second Line Patients With Metastatic Pancreatic Cancer
Dec 5, 2019 07:00AM BioLineRx Announces Preliminary Phase 2a Data from Triple Combination Arm of COMBAT/KEYNOTE-202 Study in Second Line Patients With Metastatic Pancreatic Cancer
Nov 26, 2019 07:00AM BioLineRx to Host Investor and Analyst Breakfast Meeting on December 5, 2019 in New York
Nov 11, 2019 07:00AM BioLineRx Reports Third Quarter 2019 Financial Results and Provides Corporate Update
Nov 6, 2019 07:00AM BioLineRx to Report Third Quarter 2019 Results on November 11, 2019
Nov 5, 2019 09:00AM BioLineRx Announces BL-8040 in Combination With KEYTRUDA Shows Clinical Activity in Heavily Pretreated Metastatic Pancreatic Cancer Patients
Nov 5, 2019 08:13AM UPDATE: BioLineRx (BLRX) Highlights Positive Preclinical Data From Triple Combination of BL-8040, Anti PD-1 and Chemotherapy
Nov 5, 2019 08:00AM BioLineRx Presents Preclinical Data From Triple Combination of BL-8040, Anti PD-1 and Chemotherapy Demonstrating Significant Reduction in Pancreatic Tumor Growth and Favorable Changes in Tumor Microen
Oct 31, 2019 07:00AM BioLineRx to Present Two Posters at the Society for Immunotherapy of Cancer (SITC) 2019
Oct 29, 2019 07:00AM BioLineRx to Deliver Oral Presentation at ESMO Immuno-Oncology Congress 2019
Sep 25, 2019 07:03AM BioLineRx (BLRX) Reports First Patient Dosing in Part 2 of Phase 1/2a Clinical Study for AGI-134
Sep 25, 2019 07:00AM BioLineRx Announces Dosing of First Patient in Part 2 of Phase 1/2a Clinical Study for AGI-134, a Novel Immunotherapy for Treatment of Solid Tumors
Sep 3, 2019 07:02AM BioLineRx (BLRX) Reports Complete Dose-Escalation Part of Phase 1/2a Clinical Study for AGI-134
Sep 3, 2019 07:00AM BioLineRx Successfully Completes Dose-Escalation Part of Phase 1/2a Clinical Study for AGI-134, a Novel Immunotherapy for Treatment of Solid Tumors
Aug 6, 2019 07:00AM BioLineRx Reports Second Quarter 2019 Financial Results and Provides Corporate Update
Jul 30, 2019 08:00AM BioLineRx to Report Second Quarter 2019 Results on August 6, 2019
Jun 28, 2019 04:01PM BioLineRx Announces Change in Ratio of American Depositary Shares to Ordinary Shares
Jun 13, 2019 07:00AM BioLineRx to Present at the JMP Securities 2019 Life Sciences Conference
May 14, 2019 07:00AM BioLineRx Reports First Quarter 2019 Financial Results and Provides Corporate Update
May 7, 2019 08:00AM BioLineRx to Report First Quarter 2019 Results on May 14, 2019
May 7, 2019 07:31AM BioLineRx (BLRX) Reports FDA Approval of IND Application for AGI-134
May 7, 2019 07:00AM BioLineRx Announces FDA Approval of IND Application for AGI-134, a Novel Immunotherapy Anti-Cancer Vaccine for Solid Tumors
Mar 28, 2019 07:00AM BioLineRx Reports Year End 2018 Financial Results and Provides Corporate Update
View More Recent Stories View Older Stories